EA202190463A1 - Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов - Google Patents
Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторовInfo
- Publication number
- EA202190463A1 EA202190463A1 EA202190463A EA202190463A EA202190463A1 EA 202190463 A1 EA202190463 A1 EA 202190463A1 EA 202190463 A EA202190463 A EA 202190463A EA 202190463 A EA202190463 A EA 202190463A EA 202190463 A1 EA202190463 A1 EA 202190463A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- disease
- ccr3
- function
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 | |
| PCT/US2019/052995 WO2020069008A1 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190463A1 true EA202190463A1 (ru) | 2021-06-29 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190463A EA202190463A1 (ru) | 2018-09-26 | 2019-09-25 | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (https=) |
| JP (2) | JP7528065B2 (https=) |
| KR (1) | KR20210065950A (https=) |
| CN (1) | CN112789044A (https=) |
| AU (1) | AU2019346456A1 (https=) |
| BR (1) | BR112021004938A2 (https=) |
| CL (1) | CL2021000724A1 (https=) |
| CO (1) | CO2021003713A2 (https=) |
| EA (1) | EA202190463A1 (https=) |
| IL (1) | IL281578A (https=) |
| MA (1) | MA53743A (https=) |
| MX (1) | MX2021002967A (https=) |
| SG (1) | SG11202102105VA (https=) |
| TW (1) | TW202027752A (https=) |
| WO (1) | WO2020069008A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113689A1 (en) | 2018-09-25 | 2020-04-02 | Antabio Sas | Indane derivatives for use in the treatment of bacterial infection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| MX2011011080A (es) | 2009-04-22 | 2012-02-23 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida. |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| MY199462A (en) * | 2017-04-05 | 2023-10-30 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| CN110636844A (zh) * | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
-
2019
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko not_active Withdrawn
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en not_active Ceased
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
-
2024
- 2024-07-24 JP JP2024118649A patent/JP2024153742A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004938A2 (pt) | 2021-06-01 |
| JP7528065B2 (ja) | 2024-08-05 |
| MA53743A (fr) | 2022-01-05 |
| TW202027752A (zh) | 2020-08-01 |
| CO2021003713A2 (es) | 2021-04-08 |
| AU2019346456A1 (en) | 2021-04-15 |
| KR20210065950A (ko) | 2021-06-04 |
| JP2024153742A (ja) | 2024-10-29 |
| EP3856195A4 (en) | 2022-06-22 |
| CN112789044A (zh) | 2021-05-11 |
| CL2021000724A1 (es) | 2021-10-15 |
| SG11202102105VA (en) | 2021-04-29 |
| MX2021002967A (es) | 2021-08-11 |
| IL281578A (en) | 2021-05-31 |
| JP2022502441A (ja) | 2022-01-11 |
| CA3111433A1 (en) | 2020-04-02 |
| EP3856195A1 (en) | 2021-08-04 |
| WO2020069008A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394341B (es) | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 | |
| WO2018015573A3 (en) | Trem2 cleavage modulators and uses thereof | |
| PH12018502028B1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| PH12018502101A1 (en) | Heterocyclic compound | |
| PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EA201991756A1 (ru) | Бисгетероарильные производные в качестве модуляторов агрегации белков | |
| EA201991755A1 (ru) | Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| PE20191082A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| MX2021001456A (es) | 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas. | |
| MX2020011489A (es) | Moduladores alostericos de espiropiperidina de receptores nicotinicos de acetilcolina. | |
| PE20212177A1 (es) | Compuestos y composiciones como moduladores de la senalizacion de tlr | |
| EA202190463A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
| EA201991753A1 (ru) | Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков | |
| EA201992188A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
| BR112022011810A2 (pt) | Compostos inibidores de oga | |
| WO2020092102A3 (en) | 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor | |
| NO20084819L (no) | Substituerte pyrazinonderivater for anvendelse som en medisin | |
| WO2016153957A3 (en) | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases | |
| MA54630B1 (fr) | N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives | |
| WO2006135545A3 (en) | A method for the prevention and/or treatment of neurodegenerative diseases characterized by administering an ep1 receptor antagonist | |
| EA201691232A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений |